{
    "clinical_study": {
        "@rank": "134369", 
        "arm_group": {
            "arm_group_label": "PegIFN-2b + RBV+ boceprevir", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive PegIFN-2b (once weekly, 1.5 \u00b5g/kg subcutaneously)  + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 \u00b5g/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day)."
        }, 
        "brief_summary": {
            "textblock": "This study is being done to find out if the addition of boceprevir to standard of care (SOC)\n      treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for\n      participants with chronic hepatitis C (CHC) genotype 1 and cirrhosis who were not\n      successfully treated by previous SOC.  All participants will receive treatment with SOC\n      alone for 4 weeks and then boceprevir will be added to the treatment regimen for 44\n      additional weeks of combined treatment."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Fibrosis", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Weight between 40 kg and 125 kg\n\n          -  Documented CHC genotype 1 infection\n\n          -  Previous course of treatment with SOC (PegIFN-2a or PegIFN-2b + RBV) with a\n             documented non-response\n\n          -  Documented diagnosis of cirrhosis\n\n          -  No evidence of hepatocellular carcinoma (HCC) by ultrasound\n\n          -  Participant and partner of participant must agree to use 2 effective contraceptives\n             as specified for at least 2 weeks prior to Day 1 of treatment and continue until at\n             least 6 months after last dose of study drug (7 months for male participants)\n\n        Exclusion criteria:\n\n          -  Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus\n\n          -  Use of any investigational drugs within 30 days prior to study enrollment\n\n          -  Participation in any other clinical trial within 30 days of study enrollment or\n             intention to participate in another clinical trial during this study\n\n          -  Evidence of present or previous decompensated liver disease including, but not\n             limited to, a history or presence of clinical ascites or hepatic encephalopathy. Only\n             participants with large (F3) esophageal varices, as determined in an\n             esophagogastroduodenoscopy (EGD) performed within the past 12 months according to\n             international guidelines will be excluded.\n\n          -  Clinically significant ocular examination findings\n\n          -  Pre-existing significant psychiatric condition(s)\n\n          -  Clinical diagnosis of active or recent substance abuse\n\n          -  Evidence of active or suspected malignancy, or a history of malignancy, within the\n             last 3 years (except adequately treated carcinoma in situ and basal cell carcinoma of\n             the skin)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756079", 
            "org_study_id": "3034-105", 
            "secondary_id": "2012-002772-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "PegIFN-2b + RBV+ boceprevir", 
                "intervention_name": "boceprevir", 
                "intervention_type": "Drug", 
                "other_name": "SCH 503034"
            }, 
            {
                "arm_group_label": "PegIFN-2b + RBV+ boceprevir", 
                "intervention_name": "PegIFN-2b", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Peginterferon alfa-2b", 
                    "PegIntron", 
                    "SCH 054031"
                ]
            }, 
            {
                "arm_group_label": "PegIFN-2b + RBV+ boceprevir", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ribavirin", 
                    "Rebetol"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Peginterferon alfa-2b"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Patrizia Nardini", 
                "phone": "39 06 361911"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy"
                }, 
                "name": "MSD Italia S.r.l."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105-00)", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants who achieve sustained viral response (SVR) at 24 weeks after the end of all study treatment", 
            "safety_issue": "No", 
            "time_frame": "Week 72"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}